Evolus Reports Third Quarter 2019 Financial Results and Provides Business Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall St muted ahead of Nvidia results, hot inflation fuels rate-hike bets
- Oil slips as investors focus on Hormuz talks
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Boston Scientific discloses cybersecurity incident causing global disruption
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Crude Inventory Rose 0.1 Million Barrels Last Week - EIA
- FDA approves Revolution Medicines pancreatic cancer drug Rasonque
Mizuho Securities Reiterates Buy Rating on Evolus (EOLS) Following 3Q Beat
November 5, 2019 7:22 AM ESTMizuho Securities analyst Difei Yang reiterated a Buy rating and $30.00 price target on Evolus (NASDAQ: EOLS) following the company's 3Q earnings report. Both revenue and EPS came in above consensus estimates, driven by strong sales from Jeuveau in the... More
Evolus (EOLS) Tops Q3 EPS by 15c, Revenues Beat
November 4, 2019 7:09 AM ESTEvolus (NASDAQ: EOLS) reported Q3 EPS of ($0.98), $0.15 better than the analyst estimate of ($1.13). Revenue for the quarter came in at $13.2 million versus the consensus estimate of $4.05 million.
This was an exceptional quarter for the company on many fronts, in the U.S. and internationally,... More
